As expected, impaired learning and memory by IE was markedly decreased by siRNA-Cx43 treatment (Fig. 4D, E, F; Latency to platform: day 5: F(3, 20) = 13.90, p < 0.0001, Post-hoc analysis: IE vs. siRNA-Cx43-IE group: p = 0.0013; % of time in target quadrant C: F(3, 20) = 12.79, p = 0.0002, Post-hoc analysis: IE vs. siRNA-Cx43-IE group: p = 0.0014; Target crossing times: F(3, 20) = 9.162, p = 0.0005, Post-hoc analysis: IE vs. siRNA-Cx43-IE group: p = 0.0176), whereas treatment with the nontargeted siRNA had no effect on IE-induced learning and memory impairment. The gene discussed is GJA1; the disease is memory impairment.